Adverse Events Mushroom 144% In 2007; Various Factors At Play, FDA Says
This article was originally published in The Silver Sheet
Executive Summary
ADVERSE EVENTS REPORTED TO FDA VIA ITS MDR PROGRAM continue to skyrocket, leaving agency officials to hope that a soon-to-be-mandated switch to electronic Medical Device Reporting (eMDR) will ease its workload. According to statistics from CDRH's Office of Surveillance and Biometrics, MDR reports spiked 144 percent between 2006 and 2007 - and the trend shows no signs of stopping. Currently only 12 manufacturers have joined the eMDR program, which has led FDA to reach out more aggressively to industry. “Each report that comes electronically is one less report we have to do data entry for,” says Indira Konduri, chief of OSB's Information Analysis Branch. Plus, industry experts advise firms on how to set up eMDR programs of their own.
You may also be interested in...
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.
FDA Slaps High Risk Class I Label On Recall Of COVID-19 Diagnostics Made In Uncontrolled Plant
More than 160,000 of the tests were recalled, including 104,900 COVID Test Kits Nonsterile and 61,500 Clean Catch Urine Kits.